GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
£1mln pipeline for this year alone with £850,000 cash as of annual report date amd a mere £2.5mln cap
Welcome Steve
PYC is at cutting edge of artificial intelligence in oncology and drug development
What it shows to me is while other companies are battoning down hatches PYC are expanding and growing ,these last 3 new appointment come with a good pedigree
And with a very healthy cash to market cap ratio of 1 : 3 and a growing pipeline with a record ever revenues expected in 2023/24 as stated in annual report
Another great appointment here and I will take my first steps to invest in trances today after i huge result in obd as I like this sector
Notice ,it was supported and respected the 50 ema
Buyers took control yesterday from c-3% to +c11% ,a close above 2.00 will try and test the 2.80 again
https://invst.ly/11laox
Https://www.linkedin.com/in/venkata-putcha-msc-phd-2913845/recent-activity/comments/
No doubt looking at his work experience he "gets about" Never seems to be in 1 place for more than a year and a half.
Has worked with some big pharma, inc AZ (freelance) Novartis and Roche.
Update on ths sector "before the end of the calander year "
hiring this week of a new senior member of its team, Dr Venkata Putcha, as Head of Biostatistics.
Dr Putcha brings with him over 22 years of experience working within drug development, with over 17 years working for many of the top-tier pharmaceutical and CRO companies
The Head of Biostatistics role will help to formulate and deliver on the Company's new Biostatistics service offering. The initial focus will be to build upon the Company's existing Biostatistics strategy, working with Business Development and Senior Management to define key service offerings and identify new clients. Dr Putcha will be responsible for the delivery of new Biostatistics consulting contracts within the business and, as we grow this service line, will take a lead refining and executing on the Company's Biostatistics strategy.
Dr Jim Millen, Executive Chair and CEO commented:
"Following our announcement earlier this year that Physiomics would be expanding into adjacent areas of lifesciences R&D consulting, starting with biostatistics, we are delighted to welcome Venkata to our team. His extensive experience in the field of biostatistics will act as a strong base from which to grow this new segment of our business. We'll be providing a further update on our expansion into this field later this calendar year."
Thank you Mr P
I never quite understood the deal structure. All i kept on seeing was the "upto £6m"
Porky
You can't and don't invest as you lost everything everything on DDDD hence why not once have you posted that you have purchased any single share In any company . Why did you lose it all on DDDD when the BOD were lying about their finances?...
Very odd you didn't see that coming
Instead you lurk on various chat board imparting nonsense
@share4
Every board practically on LSE just becomes an echo chamber for rampers, dare try and evaluate or give a different view and your toast. Half the time its not worth the effort.
When i invest, i want all views good and bad, i cant evaluate in an echo chamber hence most boards offer me little advantage.
Good luck to you
@Siennaj
FYI i actually like this business and i specifically like Jim who is a really decent guy and honest broker. He has my maximum respect trying to build this business in challenging conditions.
@kidlington
Sure - The deal agreed an initial consideration of £1.3m to Val, the deal signed by PYC agreed a 6% fee hence £ 78k due on the first payment. The other milestones VAL agreed are based on IF the drug enters trials and if the drug has success at those said trials. I had zero confidence that THX would ever get any funding tbh but a tweet from Patrick Frankham after close tonight hints to funding, so tomorrow they may confirm same. Of course we don't know if enough cash to start trials or milestone results that's another matter and that's way ,way off and wont help PYC short term if at all.
But the £78k would come in useful to Jim if that comes over the line this year that's for sure.
Good luck
@Porky
They get upset when you simply state facts. The level of angry immoral characters looking for a quick buck on these boards is extensive.
Mr P can you show or tell me how you came to those figures in your post pls?
tia
The Company completed its observational "PARTNER" study at Portsmouth University Hospitals NHS Trust which validated the ability of the tool to predict levels of neutropenia. Although this was felt to be of interest by clinicians, it was determined that the tools use to guide the use of the expensive biological drug GCSF (used to counteract neutropenia) might have a higher commercial value and the Company is currently actively exploring ways to further develop its tool to facilitate this.
During the year, the Company's US partner DoseMeRx announced that it had been divested by its owner Tabula Rasa Healthcare (TRHC) and acquired by a private equity company. Since then, the Company has re-established contact with DoseMeRx and discussions are ongoing around how the Company's tool might be used in the US.
Share 4 and Porky . You are both extremely irritating. If you don't like this company then get lost. I don't like the fact you reported Laura. Share 4 you are so trivial
Ironmighty
Posts: 400
Price: 7.85
No Opinion
TheoremRx tweet 16.30Today 16:44
Https://x.com/patrickfrankham/status/1708867845336007065?s=46&t=xdsQNV0n_ZHRmadh3y3aIA
Patrick Frankham (CEO TheoremRx):
Taking biotech startups from concept to identifying suitable druggable assets to a risk adjusted portfolio to a fundable business case in todays macro-environment is challenging but still achievable in the US. #stealthmodebio
@Share4
A heck of a lot of ramping on VAL board today and removal of posts not agreeing.
IMO the THX wont pay VAL anything, its "The Emperor's New Clothes" that people are buying into today.
Just amazed you can still fool some of the people some of the time.
As for PYC the deal is worth exactly £ 78,000 to them IF it was paid up to VAL at £1.3m but i put that event at absolute zero.
At least you got a lift here on the back of that hype, which is a positive for holders.
Good luck share4. Not sure why you pollute this board.
This could be very good news for PYC....
Good luck, Brighty
appears that the 201 deal is about to be signed. That will bring significant payments. Also the lab is fully set up to bring in revenue generating contracts.
Worth watching the first 10 minutes of the presentation. TRX has now also made public the website
Oh it's up to 850 cash now! That's an extra 50k already. Just ignore the fact that they've been losing money every month too!
At least porky didn't hide his posting history by getting all his posts deleted and changing his handle. Honest people don't do that.
Up to £6mln due to PYC
£1mln pipeline for this year alone with £850,000 cash as of annual report date amd a mere £2.5mln cap
According to VAL Q and A it is close is close be being signed
Ignore porky
He lost £1000s on DDDD and NCYT and now spends 2yrs plaguing VAL board